Bionano Genomics- Warrants (21/08/2023) Accounts Payable

The latest accounts payable for BNGOW is $4.6M as of June 2026. That compares with $6.2M in the prior-year period — down 26.9% year over year. Investors often review this figure alongside Bionano Genomics- Warrants (21/08/2023)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, BNGOW's accounts payable moved from $6.2M to $4.6M — a 26.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Bionano Genomics- Warrants (21/08/2023)'s operating scale or balance-sheet position.

A accounts payable figure of $4.6M for BNGOW is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting BNGOW's accounts payable ($4.6M), review year-over-year change from $6.2M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Bionano Genomics- Warrants (21/08/2023)'s accounts payable against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.